Formulation and Evaluation of Mouth Dissolving Tablet Rivaroxaban and its Validation

The foremost intention of present research was the preparation and assessment of mouth dissolving formulation Rivaroxaban and its validation. During present work, this tablet was formulated by straight compression technique by means of Cros-carmellose sodium and Sodium starch glycolate as super-disi...

Full description

Saved in:
Bibliographic Details
Published in:Biosciences, biotechnology research Asia biotechnology research Asia, 2022-12, Vol.19 (4), p.943-954
Main Authors: B. Borse, Laxmikant, Bendale, Atul R., L. Borse, Sandhya, D. Naphade, Vaishali, G. Jadhav, Anil
Format: Article
Language:English
Subjects:
Bioavailability
Buffers
Calibration
Disintegration
Drug dosages
Dysphagia
Friability
Hardness tests
Mathematical analysis
Mouth
Parameters
Sodium
Solvents
Spectrophotometry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The foremost intention of present research was the preparation and assessment of mouth dissolving formulation Rivaroxaban and its validation. During present work, this tablet was formulated by straight compression technique by means of Cros-carmellose sodium and Sodium starch glycolate as super-disintegrants (concentration of 2, 4, 6%) and Avicel 102 as a binder. The formulated preparations were exposed to different consideration parameters like hardness test, friability test, disintegration test, release of drug and content of drug. The calibration curve of API using solvent phosphate buffer pH 6.8 was carried out. All prepared formulations exposed to different assessment parameters have shown the findings within prescribed limit. Due to the large concentration of super disintegrants in F8, disintegration time can reach 29±0.06 seconds. In used buffer, drug release was calculated at intervals of 0, 2, 4, 6, 8, 10, and 12 minutes. The F8 demonstrates 96.5±0.567 percent medication release. UV spectrophotometric validation was performed for the quantification of Rivaroxaban in bulk. Rivaroxaban was estimated at 247nm in phosphate buffer 6.8. The linearity range was observed 2–12µg/ml.
ISSN:0973-1245
2456-2602
DOI:10.13005/bbra/3043